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Thiazolides Elicit Anti-Viral 
Innate Immunity and Reduce HIV 
Replication
Daria Trabattoni1,*, Federica Gnudi1,*, Salomè V. Ibba1, Irma Saulle1, Simone Agostini2, 
Michela Masetti1, Mara Biasin1, Jean-Francois Rossignol3 & Mario Clerici2,4
Nitazoxanide (Alinia®, NTZ) and tizoxanide (TIZ), its active circulating metabolite, belong to a class 
of agents known as thiazolides (TZD) endowed with broad anti-infective activities. TIZ and RM-4848, 
the active metabolite of RM-5038, were shown to stimulate innate immunity in vitro. Because natural 
resistance to HIV-1 infection in HIV-exposed seronegative (HESN) individuals is suggested to be 
associated with strong innate immune responses, we verified whether TIZ and RM-4848 could reduce 
the in vitro infectiousness of HIV-1. Peripheral blood mononuclear cells (PBMCs) from 20 healthy donors 
were infected in vitro with HIV-1BaL in the presence/absence of TIZ or RM4848. HIV-1 p24 were measured 
at different timepoints. The immunomodulatory abilities of TZD were evaluated by the expression of 
type I IFN pathway genes and the production of cytokines and chemokines. TZD drastically inhibited 
in vitro HIV-1 replication (>87%). This was associated with the activation of innate immune responses 
and with the up-regulation of several interferon-stimulated genes (ISGs), including those involved 
in cholesterol pathway, particularly the cholesterol-25 hydroxylase (CH25H). TZD inhibition of HIV-1 
replication in vitro could be due to their ability to stimulate potent and multifaceted antiviral immune 
responses. These data warrant the exploration of TZD as preventive/therapeutic agent in HIV infection.
Alinia® (NTZ) is a first-in-class thiazolide (TZD) with an in vitro activity against parasites, anaerobic bacteria, 
and viruses1–3. This compound is currently approved in the United States in the treatment of diarrhea caused 
by Cryptosporidium parvum and Giardia intestinalis4,5. It is also approved in Latin America, Egypt, India and 
Bangladesh for the therapy of a broad range of intestinal protozoan and helminthic infections, and is available 
upon Emergency Use Authorization in Canada, Australia, Japan and the European Union. NTZ and its active 
metabolite tizoxanide (TIZ) also inhibit the replication of a broad range of RNA and DNA viruses, and NTZ 
was shown to be effective in clinical trials against diarrhea caused by rotavirus and norovirus, uncomplicated 
influenza A and B, as well as hepatitis B (HBV) and C (HCV) infections6–12. A large number of thiazolides closely 
related to the chemical structure of NTZ have been recently synthesized and tested for their anti-viral activity. 
RM-5038 in particular, whose active circulating metabolite is known as RM-4848, was selected for complete 
development due to its efficacy against C. parvum11–13. The wide spectrum of thiazolides activity was recently 
confirmed by in vitro data indicating an effect of these compounds against HIV. Thus: 1) the association between 
reverse transcriptase inhibitors (RTI) and NTZ is effective against HIV-1 replication14, and 2) NTZ decreases 
HIV-1 replication in monocyte-derived macrophages (MDM)15.
We have recently shown that TIZ and RM-4848 up-regulate a number of genes involved in the TLR- and 
type I IFN signal transduction pathways [Trabattoni D. and Gnudi F. Personal Communication]. In particular, 
thiazolides increased the expression of TLR7 and 8, molecules that sense viral-derived components and trigger 
immune responses against RNA and DNA viruses via the induction of type I IFNs. Type I IFNs are essential anti-
viral proteins that activate a wide array of effectors collectively indicated as IFN-stimulated genes (ISGs). Many 
of these ISGs inhibit viruses at particular stages of their life cycle16–20 and were shown to be upregulated in HIV-1 
exposed seronegative individuals (HESN)21,22.
Natural resistance to HIV-1 is thought to result from a favorable genetic and immunologic milieu that, if 
reproduced in individuals that are not naturally gifted by such favorable profile, could result in induced resistance 
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to this virus21,22. TLR7 and 8 stimulation, in particular, was shown to elicit strong innate immune responses and 
the transcription of ISGs with antiviral properties in HESN23. Because in vitro exposure of PBMCs to thiazolides 
stimulates the activation of an immune profile that resembles that observed in HESNs, and NTZ was shown to 
have an antiviral activity that synergizes with that of other drugs, we verified whether in vitro susceptibility to 
HIV infection could be modulated by TIZ or RM-4848.
Results
Evaluation of TZDs cytotoxicity in HIV-1-infected cells. Cell viability was analyzed in HIV-1-infected 
cells cultured in the presence of different doses of TIZ or RM-4848 (1, 5, 10, 20 and 100 μ g/ml) by MTT assay. 
Results indicated that, with the exception of the highest dose, neither TIZ nor RM-4848 alter the viability of 
PBMCs (Fig. 1a,b respectively). To perform all the experiments a dose of 10 μ g/mL of compounds was chosen 
based on preliminary results showing that concentrations lower than 20 μ g/mL are sufficient to maintain pharma-
cological properties without affecting cell viability [Trabattoni D., Gnudi F. Personal Communication].
Antiviral activity of TZDs against HIV-1BaL infection in vitro. In vitro infection of PBMCs with HIV-1 
was significantly and consistently reduced by TIZ and RM-4848; this effect was reproduced in all the experiments 
(n = 20) in which cells from randomly selected donors not carrying genetic markers known to reduce susceptibil-
ity to HIV infection were used (see Methods). The overall inhibition of HIV-1 replication in vitro was 87.8% for 
TIZ and 96.5% for RM-4848 (p-value < 0.01 vs. medium alone) at a 10μ g/mL concentration (Fig. 2a,b).
The antiviral effect of RM-4848 was further examined by adding this compound to cell cultures at different 
time-points: 1) for two days before HIV-1 infection and then washed away (pre-infection); 2) during the 24 hours 
infection period infection followed by washout; or 3) 24 hours after infection and untill the end of the cell culture 
period. Cells infected with HIV-1 in the presence of RM-4848 throughout infection (RM-4848) (10 μ g/mL) or 
in medium alone (no treatment) were considered as controls. The strongest inhibition of viral replication was 
observed when RM-4848 was added to the cultures at the time of infection, or one day after infection (Fig. 2c).
Modulation of type I IFN pathway by TZDs. The ability of thiazolides to up-regulate type I IFN and ISG 
expression levels in this model of in vitro HIV-1-infection was analyzed in PCR array that screens simultaneously 
84 genes involved in the type I IFN pathway. Exposure of PBMCs to TIZ resulted in an increased expression of 
a number of IFNs (IFNα 1, IFNα 2, IFNα 4, IFNβ 1, IFNγ ) and ISGs (ARL5B, IRF7, MET, OAS2, PRKRA, SHB, 
STAT2, TRAF3), as well as of HLA-C (Fig. 3a). Upon HIV-1 infection this effect was potentiated and amplified, 
and different genes were strongly up-regulated. These included IFNs (IFNα 1, IFNα 2, IFNα 4, IFNβ 1, IFNγ ), ISGs 
Figure 1. Percentage of cell viability after culture with different doses of TIZ (1, 5, 10, 20 and 100 μ g/ml) (a) or 
RM4848 (1, 5, 10, 20 and 100 μ g/ml) (b) at different time-points (1, 3, 5 and 10 days) assessed using an MTT 
assay.
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(IFIT1, IFITM2, IRF1, IRF2, IRF7, ISG15, ISG20, MX1, MyD88, OAS2, PRKRCZ, SHB, STAT2, TRAF3), HLA-C 
and CD70, an important immunoregulatory receptor (Fig. 3a). In all conditions the effect of RM-4848 was more 
robust than that of TIZ (Fig. 3b).
Analysis of anti-HIV-1 human response pathway. Results above show that thiazolides induce the 
up-regulation of genes such as IRF1, OAS2 and PRKRA known to obstacle HIV infectivity. To analyze more in 
depth whether the anti-HIV effects of TZDs stem from the modulation of cellular factors involved in the HIV-1 
life cycle, we used an anti-HIV-1 human response pathway array that screens for the expression of such factors. 
Results indicated that the in vitro HIV-inhibitory properties of TZDs are only partially explained by the modula-
tion of HIV-1 life cycle genes. Also in these experiments the antiviral activity of RM-4848 was more potent than 
that of TIZ (Fig. 4).
TZDs modulate cytokine and chemokine production in HIV-1 infected PBMCs. Cytokine and 
chemokine production by HIV-infected PBMCs in the presence of thiazolides was measured next. Results showed 
that IFNγ and IL-2 production was significantly increased in HIV-1 infected cells by both TIZ and RM-4848 
(p < 0.05 vs. medium alone). Even more interestingly, the production of those CC chemokines known to be 
endowed with potent anti-HIV activities (MCP-1, MIP1-α , MIP1-β , RANTES) was modulated by both TIZ 
(Fig. 5a) and RM-4848 (Fig. 5b) (p < 0.05 vs. medium alone). These results suggest that thiazolides obstacle viral 
entry and/or reduce the infection process of target cells.
TZDs up-regulate ISG involved in cholesterol metabolism. Since thiazolides up-regulate type 1 IFN 
and ISGs, and because ISGs involved in the metabolism and the efflux of cholesterol were recently shown to have 
a potent antiviral activity, we verified whether these compounds may also affect cholesterol metabolism, and in 
Figure 2. (a) p24 viral antigen levels 10 days post-infection in the supernatant of HIV-1 infected PBMCs treated 
with TIZ (10 μ g/mL) or RM-4848 (10 μ g/mL). Results obtained with PBMC of 20 different healthy donors are 
shown. Median values and statistical significance is presented. (b) Inhibition (%) of viral replication in PBMC of 20 
different healthy donors infected in vitro with HIV-1 in the presence of TIZ- (10 μ g/mL) or RM-4848- (10 μ g/mL). 
Median values and statistical significance is presented. (c) p24 viral antigen levels in PBMCs infected with HIV-1 
in the presence of RM-4848 throughout infection (RM-4848)(10 μ g/mL) or in medium alone (no treatment). 
In addition to these two situations, results of 3 other experimental conditions are shown: 1) PBMCs treated 
with RM-4848 before being infected (pre-infection); 2) RM-4848 present during the 24 hours infection period 
(during infection) and then washed away; 3) RM-4848 added 24 hours after infection (post infection). Mean 
values ± standard errors are shown.
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particular CH25H expression. Results obtained in uninfected PBMCs confirmed this hypothesis, showing an 
up-regulation of genes involved in cholesterol metabolism and efflux and of different membrane receptors and 
cholesterol transporters both by TIZ (Fig. 6a) and RM-4848, with the effects of this latter compound once again 
being more potent (Fig. 6b).
These effects were more pronounced upon HIV-1 infection as TIZ and, mostly, RM-4848 up-regulated the 
expression of proteins (CH25H, CYP7B1, LXRα , LXRβ , PPARγ , RXRα , RXRβ SREBF1, and SREBF2) and mem-
brane receptors (MSR1, SCARB1, LDLR, ABCG1 and ABCA1) involved in cholesterol metabolism and efflux 
(Fig. 6c,d). CH25H, in particular, an enzyme recently shown to play a role in preventing viral spread to target cells 
HIV20, was robustly (> 12 fold) up-regulated by thiazolides in HIV-1-infected cells.
Thiazolides upregulation of Interferon-Inducible Cholesterol-25-Hydroxylase (CH25H). Activation 
of CH25H results in an enzymatic reaction that generates 25-HC, a natural oxysterol that mediates the efflux of 
cholesterol from cells and ligates the liver X receptor (LXR). To analyze possible correlations between genes involved 
in cholesterol efflux and in vitro inhibition of HIV-1 infection we stimulated HIV-1-infected cells with a synthetic 
agonist of LXR (TO-901317) and assessed viral infectivity. Results showed that agonist-mediated activation of LXR 
resulted in a significant decrease of cell infection (52%; p < 0.01) (Fig. 7), suggesting that the protective effects of 
thiazolides on HIV-1 infectivity are at least partially achieved through the modulation of cholesterol efflux 
mechanisms.
Discussion
The vast spectrum of antimicrobial activity of thiazolides was recently enriched by results indicating that these 
compounds are effective in reducing in vitro HIV infection14,15. We investigated the immunologic basis of this 
effect and show herein that incubation of PBMCs with thiazolides results in the secretion of type 1 cytokines 
and of CC chemokines, as well as the upregulation of type I IFN genes and interferon-stimulated genes (ISGs). 
Figure 3. mRNA expression of 84 genes that are part of the type I IFN signal transduction pathway has 
been assessed by real-time quantitative RT-PCR, calculated relative to five housekeeping genes and shown 
as fold-change expression from the untreated sample. Gene expression (nfold) is shown as a color scale from 
green to red (− 2 to + 9) (MEV multiple experiment viewer software). (a) Uninfected and HIV1-infected (day 7 
post infection) PBMCs cultured in medium containing TIZ (10 μ g/mL); (b) Uninfected and HIV1-infected (day 
7 post infection) PBMCs cultured in medium containing RM-4848 (10 μ g/mL). Only targets showing at least a 
2-fold modulation were considered significative and shown in tabs.
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Figure 4. mRNA expression of 84 genes that are part of the HIV-1 life cycle and known to directly obstacle 
HIV infectivity has been assessed by real-time quantitative RT-PCR, calculated relative to five housekeeping 
genes and shown as fold-change expression from the untreated sample. Gene expression (nfold) is shown as a 
color scale from green to red (− 2 to + 9) (MEV multiple experiment viewer software). Results were obtained in 
HIV1-infected PBMCs at day 7 post infection, cultured in medium containing TIZ (10 μ g/mL) or RM-4848  
(10 μ g/mL). Only targets showing > 2-fold modulation are considered significant and are shown in tab.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:27148 | DOI: 10.1038/srep27148
Figure 5. Cytokines (IL-2, IFNγ) and chemokines (MCP-1, MIP-1α, MIP-1β, RANTES) production (pg/ml) 
by PBMCs of healthy donors. PBMCs were either uninfected (white bars) or HIV-1-infected (grey bars) and were 
cultured in medium alone (no drug), or in medium containing either TIZ- (10 μ g/mL) (a) or RM-4848- (10 μ g/mL) 
(b). Mean values 7 days post-infection ± standard errors and statistical differences are shown.
Figure 6. mRNA expression of genes involved in cholesterol metabolism and efflux in PBMCs of healthy 
donors. (a) Uninfected PBMCs cultured in medium containing TIZ (10 μ g/mL); (b) Uninfected PBMCs 
cultured in medium containing RM-4848 (10 μ g/mL); (c) HIV-1–infected PBMCs (day 7 post infection) 
cultured in medium containing TIZ (10 μ g/mL); (d) HIV-1–infected PBMCs (day 7 post infection) cultured 
in medium containing RM-4848 (10 μ g/mL). Gene expression genes is assessed by quantitative RT-PCR and 
shown as fold-change expression from the untreated sample. Only targets showing > 2-fold modulation are 
considered significant. Mean values ± S.D. and p values are indicated.
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This effect was potentiated upon exposure of cells to HIV, and is associated with a significantly and reproducible 
reduction of HIV infectiousness of lymphocytes isolated from healthy individuals.
These results indicate that TZDs hamper HIV-1 infection of target cells and reduce viral replication using 
different and possibly overlapping modalities. Thus: 1) CC chemokines, whose production is stimulated by TZDs, 
impede the infection of target cells by CCR5 tropic viruses24,25, 2) Type 1 cytokines and cell-mediated immune 
responses contrast HIV-1 replication26,27, and 3) the stimulation of the transcription rate of genes endowed with 
generic antiviral effects, or know to have a specific ability to obstacle HIV-1 replication by TZDs, likely con-
tributes to the anti-HIV properties of these compounds. Amongst the genes with generic antiviral effects that 
are upregulated by TZDs the activity of these compounds on: 1) PRKRA, a protein kinase activated by dsRNA 
that inhibits cellular mRNA translation and the synthesis of viral proteins18,26, 2) ADAR, an enzyme that dest-
abilizes double-stranded RNA through conversion of adenosine to inosine28, 3) OAS2, which activates RNAses 
and induces the degradation of viral RNA and the inhibition of protein synthesis29, and 4) STAT2, a protein that 
activates the transcription of ISG and drives infected cell in an antiviral status30, is likely very important. Within 
genes that are upregulated by thiazolides and have a direct anti HIV-1 activity, IRF-1 a protein required for effi-
cient HIV-1 replication31, and MX2 which acts as an inhibitor of HIV-1 infection by blocking viral replication at 
a late post-entry step, could play pivotal roles32,33. Notably, recent observations showed that IFN effectors work 
in cooperation to achieve a fully functional antiviral state, i.e., combination of different ISGs expressed together, 
such as what is observed in TZDs-treated cells, results in an ampler magnitude of antiviral activity than either 
gene alone34. These results would explain the greater efficacy of RM-4848 compared to TIZ in reducing HIV-
1-infection, given the fact that RM-4848 results in the upregulation of a broader range of ISGs compared to what 
is seen in cells exposed to TIZ.
The observation that CH25H, an oxysterols-producing enzyme, is up-regulated by TIZs, is particularly 
intriguing. Viral infections themselves results in the rapid induction of CH25H and the consequent production 
of 25-HC via STAT1, a type I IFN effector. Interestingly, 25HC inhibits the growth of a wide range of enveloped 
viruses by inducing structural changes in the cellular membrane that impair viral entry at the virus-cell fusion 
step20. Our data show that thiazolides indeed up-regulate the expression of a number of genes that are part of 
cholesterol metabolism. Thus, the transcription factors of the sterol regulatory element–binding protein (SREBP) 
family, SREBP1 and SREBP2 are involved in the regulation of cholesterol biosynthesis35. Macrophage scavenger 
receptor-1 (MSR-1)36 and the LDL receptor (LDL-R)37 are responsible for the influx of lipids into macrophages. 
Finally, liver X receptor (LXR) α , and the peroxisome proliferated factor (PPAR) γ coordinate the removal of 
intracellular cholesterol36,38. Notably, TZDs also increased the expression of genes that encode lipid-transport 
proteins, such as the ATP-binding cassettes A1 (ABCA1) and G1 (ABCG1), by which intracellular excess of cho-
lesterol is transported to extracellular acceptors35,39. The observations that: 1) thiazolides reduce in vitro HIV-1 
infection; 2) TZDs up regulate LXR; and 3) in vitro HIV-1 infection of immune cells is significantly reduced by 
LXR agonists allow the speculation that the antiviral effects of these compounds are at least partially mediated by 
their ability to modulate proteins within the cholesterol metabolic pathway. Notably, this is a speculative hypoth-
esis that will need to be tested in furhter experiments.
These results indicate that TZDs are endowed with strong and multifaceted antiviral activities, and confirm 
previous in vitro observations14 suggesting that the use of these compounds might be envisioned in the ther-
apy of HIV infection. In this light, preliminary results from a clinical study carried out in the United States 
in treatment-naïve HIV-HCV co-infected subjects are interesting. In this pilot study the activity on HIV viral 
loads (VL) of nitazoxanide (NTZ) alone and in combination with pegylated- interferon and ribavirin (PEG-IFN/
RBV) was evaluated. At baseline, HIV VL was available in 65 cases; after 16 weeks of NTZ in combination with 
PEG-IFN/RBV, HIV VL was undetectable (< 20 copies/ml) in 12 of the 14 (86%) patients in whom it could be 
reanalyzed. Notably, 5 of these 14 individuals were ARV-naïve throughout the study period; median HIV VL 
Figure 7. p24 viral antigen concentration in HIV-1- infected PBMCs cultured in medium alone (no drug) 
or in the presence of TO-901317 (1 μM), an LXR agonist. Results were obtained with PBMCs of 20 different 
healthy donors 10 days post-infection. Mean values ± standard errors and statistical significance are shown.
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log10 change in these patients was − 1.32; this effect was presumably mediated by NTZ (J. F. Rossignol, Personal 
Communication). These results should be interpreted with caution not only because of the small sample size 
and lack of a direct comparator, but also because the subjects had low viral loads at baseline, making the overall 
change in HIV VL difficult to quantify. These data nevertheless support the suggestion that NTZ may have a clin-
ical benefit in patients infected with HIV.
Results herein show that the mechanism of activity of thiazolides is entirely new and is mediated by the acti-
vation of multiple and possibly synergistic mechanisms. Such mechanisms might confer to immune cells isolated 
from healthy individuals an “HESN-like” status, characterized by a drastic reduction of susceptibility to in vitro 
HIV infection. Additional disease models as well as clinical trials will be needed to elucidate the possible role of 
thiazolides in novel preventive and therapeutic approaches against HIV-1 infection and, possibly for the therapy 
of pathologies associated with alterations of the cholesterol metabolism.
Methods
Thiazolides. TIZ and RM-4848 were supplied by Romark Laboratories, L. C. (Tampa, Florida) and were 
suspended in dimethyilsulfoxide (DMSO, Sigma Aldrich, St. Louis, MO, USA) to obtain a 40 μ g/ml solution and 
stored at 2–8 °C until use.
HIV-1 strains. The laboratory-adapted HIV-1 strain used in the experiments was the R5 tropic HIV-1BaL 
(courtesy of Drs. S. Gartner, M. Popovic and R. Gallo; NIH AIDS Research and Reference Reagent Program) 
provided through the EU program EVA centre for AIDS Reagents (NIBSC, Potter Bars, UK). In initial experi-
ments two other HIV-1 strains were used: HIV-1IIIB, a subtype B CXCR4-tropic strain, and HIV-1DU174, a subtype 
C CCR5-tropic strain. Because results obtained with HIV-1BaL, HIV-1IIIB and HIV-1DU174 were always comparable, 
HIV-1BaL alone was used in the experiments presented in the paper.
PBMC isolation and HIV-1 infection. Whole blood was collected from 20 healthy volunteers by venipunc-
ture in Vacutainer tubes containing EDTA (Becton Dickinson, Franklin Lakes, NJ), and PBMCs were separated 
on lymphocyte separation medium (Organon Teknica, Malvern, PA). Subjects expressing genetic markers known 
to be associated with a reduced susceptibility to in vitro HIV infection (CCR5Δ 32; HLA-B27 and –B7; CCL3L1 
as well as SNPs in APOBEC3G, TRIM5α and MX2) were excluded from the analyses. Healthy volunteers signed a 
informed consensus, as agreements between the University of Milan and the Vimercate Hospital, (Vimercate, MB, 
Italy). This protocol was reviewed and approved by the Ethics Committee of the Luigi Sacco University Hospital 
in Milan.
All the procedures were carried out in accordance with the GLP guidelines adopted in our laboratory. PBMCs 
(2 × 106 cells/mL) were re-suspended in medium containing 1 ng/1 × 106 cells of HIV-1BaL p24 viral input and 
incubated for 24 hours at 37 °C and 5% CO2. Cells were then washed and re-suspended in complete medium with 
interleukin-2 (IL-2, 15 ng/mL) (Sigma-Aldrich, St. Louise, MO, USA) and phytohemagglutinin (PHA, 7.5 μ g/mL) 
(Sigma-Aldrich) for 3 days. After viability assessment cells were washed and re-suspended in RPMI complete 
medium with IL-2 (15 ng/ml) and TIZ (10 μ g/mL), or RM-4848 (10 μ g/ml). 50% of the culture medium was 
renewed every 3 days. PBMCs were collected for gene expression at day 7 and 10 post-infection. In some experi-
ments the conditions were modified as follows: 1) TZDs added to cell cultures before infection and then washed 
away; 2) TZDs added to cell cultures at the same time of HIV, left during the infection period (24 hours), and 
subsequently washed away; 3) TZDs added post-infection and left in the culture wells throughout the 10 days 
experiment period. Finally, in other experiments, the LXR agonist TO901317 (1 μ M/mL) (Sigma-Aldrich) was 
added to the cultures post HIV-1 infection.
Evaluation of the toxicity of TZDs. Cells were cultured in RPMI medium (Euroclone, Milan, Italy) sup-
plemented with 20% FBS (Euroclone, Milan, Italy), penicillin and streptomycin, L-glutamine and gentamycin 
(Euroclone, Milan, Italy) alone or in presence of increasing concentration (0.5 μ g/ml, 1 μ g/ml, 10 μ g/ml, 20 μ g/ml 
and 100 μ g/ml) of drugs, diluted in medium culture for 1, 3, 5, 7 and 10 days. Every two days the 50% of medium 
was removed and replaced with fresh medium containing drugs at the corresponding concentrations. Toxicity 
of thiazolides was determined by a MTT based assay (Sigma Aldrich, St. Louis, MO, USA) according to manu-
facturer’s protocol. PBMCs viability were established by dividing the absorbance reading of the formazan by the 
dry weight of cell cultures. Toxicity were determined by dividing viability of the drug- treated cells by viability of 
untreated cell control.
HIV-1 replication. Culture supernatants were collected at day 3, 7 and 10 after infection. p24 concentration 
was assayed using the Alliance HIV-1 p24 Antigen kit (Perkin Elmer, Boston, USA) following manufacturer’s 
instructions.
Cytokine and chemokine measurement. Cytokines and chemokines concentration (IL2, IFNγ , MCP-1, 
MIP1α , MIP1β and RANTES) was assessed in supernatants of uninfected and HIV-1 infected cells cultures using 
multiplex sandwich immunoassays (Fluorokine Multi Analyte Profiling Kit; R&D Systems, Minneapolis, MN, 
USA) according to manufacturer’s protocol. Supernatants were obtained after 7 days of infection.
RNA extraction and Retro-transcription (RT). RNA was extracted from 1 × 106 PBMCs by using the 
acid guanidium thiocyanate–phenol–chloroform method. RNA was dissolved in RNase-free water, and purified 
from genomic DNA with RNase-free DNase (RQ1 DNase, Promega, Madison, Wisconsin, USA). One microgram 
of RNA was reverse transcribed into first-strand cDNA in a 20-μ l final volume containing 1 μ M random hexanu-
cleotide primers, 1 μ M oligo dT and 200 U Moloney murine leukemia virus reverse transcriptase (Clontech, Palo 
Alto, California, USA).
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Real time PCR. cDNA quantification was performed by real-time PCR (DNA Engine Opticon 2; MJ 
Research, Ramsey, MN). Reactions were performed using a SYBR Green PCR mix (Promega, Fitchburg, WI, 
USA) and amplified according to the following thermal profile: initial denaturation (95 °C, 15 minutes) followed 
by 40 cycles of 15 seconds at 95 °C (denaturation) and 1 minute at 60 °C (annealing) and 20 seconds at 72 °C 
(extension). A Ct value of 40 or higher means no amplification and this value was not included in the calculations. 
Results were expressed as Δ Δ Ct and presented as ratio between the target gene and the GAPDH housekeeping 
mRNA. All the samples were analyzed in triplicate.
TLR, Type I IFN and HIV-1 human response pathway analysis. TLR, type I IFN and HIV-1 human 
response pathway were analysed in a PCR array including a set of optimized real-time PCR primer assays 
(SABiosciences Corporation, Frederick, MD, USA). This approach permits monitoring of mRNA expres-
sion of 84 genes related to the different pathways, plus five housekeeping genes. Results were analysed using 
the SABiosciences online software. Only targets showing > 2-fold modulation were considered significant. 
Experiments were run on the subjects included in the study pooled into distinct groups (medium alone, TIZ or 
RM-4848) and represent the mean value of the different targets analyzed in each group.
Statistical analysis. Comparisons between groups were analyzed to evaluate immunological differences. 
Kruskal & Wallis analysis of variance was performed for each variable; Bonferroni correction was applied to the 
results. Two-sided p-values were considered. Data analysis was performed using the SPSS statistical package 
(SPSS Inc. Chicago, IL, USA).
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